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The reason for failure of chemotherapy is often the developmenl of multidrug resistance, which is caused by the elevated level of ABC (ATP 
binding cassette) type transporters. One of the most often described ABC transporter is encoded by the MDRl (multidrug resistance l) 
gene. It was earlier described that drug induced upregulation of MDRl is associated with increased H3 acetylation level in discrete region 
of MDRl locus. Therefore exploration of the epigenetic mechanisms that contribute to the development of multidrug resistance has great 
importance. Several human diseases may originate from impaired function of histone acetyl transferases (HATs): therefore, these enzymes 
will serve as novel molecular targets for therapy in the future. 
We aimed to study the changes in specific histone acetylation upon MDRl gene induction and to analyze the histone acetyl transferase 
complexes that are responsible for these modifications. 
We characterized a drug resistant. MCF7-derived, breast carcinoma cell line named MCF-KCR. Il was generated via long temi treat-
ment of MCF7 cells with doxorubicin. We examined the level of MDRI gene and mRNA in these cell lines. We found that the MDRI gene 
level is 17 fold while the mRNA level 23000 fold elevated in the drug-resistant cells compared to the parental cells. These data suggest that 
epigenetic upregulation of MDRl transcription is more important in developing the drug resistance than gene amplification. Importantly, 
the level of MRP1 (multidrug resistance protein 1) mRNA was not elevated in the drug resistant cells. 
We showed by immunoblotting that the global H3 acetylation is elevated in the MCF-KCR cells. In addition, we examined the histone 
acetylation pattern in the regulatory regions (two promoters) and the coding region of the MDRl gene by employing chromatin immu-
noprecipitation. Our data reveal an interesting acetylation map. With the use of acetylated residue specific antibodies we found that the 
acetylation level of H3K9 is about 100 fold elevated in the downstream promoter region and in the first exon in the drug resistant subline 
compared to the drug sensitive cells. H3K4. H3K14 and H4K12 are also slightly increased in the downstream promoter region and in the 
first exon of the MDRl gene in those cells that overexpress MDRl mRNA (Toth et al. 2009). 
When we treated the cells with trichostatin A (TSA). a histone deacetylase inhibitor, MDRl expression increased, while that of the 
other genes examined did not change in the drug sensitive cells. In contrast. MDR I mRNA level did not change in the drug resistant cells 
upon TSA treatment. To try to down-regulate the acetylation and. along with that, the expression of the MDR 1 gene, we treated the cells 
with a novel HAT inhibitor (HATi II) that strongly inhibits p300 and CBP (CREB binding protein) and weakly inhibits PCAF (p300/CBP 
associated factor) and GCN5 (homolog of yeast general control nonderepressable). Importantly, expression of MDR 1 was further increased 
in the drug resistant MCF-KCR cells, while it did not change in the parental MCF7 cells. Next, we knocked down the level of PCAF. GCN5 
and Ada2b (homolog of yeast alteration/deficiency in activation 2b) mRNA by transfecting specific siRNAs. The latter is a component of 
GCN5 containing multisubunit HAT complexes, such as hTFTC/hSTAGA. Interestingly. PCAF downregulation resulted in a reduction of 
the MDRl mRNA level in MCF7 cells but not in the MCF-KCR cells. MDRl mRNA level did not change in the drug resistant subline 
and decreased only slightly in drug sensitive cells upon GCN5 or Ada2b knockdown. These data suggest that MDRl expression can not 
be easily reduced by simple inhibition of HATs in the drug resistant cells, probably because histone acetylation is highly deregulated in 
these cells. 
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Regulation of transcription, the synthesis of RNA from a DNA template, is one of the most important steps in control of cell growth and 
differentiation. Gene regulation occurs in the context of chromatin where recruitment of chromatin remodeling complexes such as ATP-
dependent remodeling complexes and histone modifying enzymes (HAT. HDAC. HMT. etc.) represents a crucial step in gene transcription 
(Svejstrup 2004). We are interested in studying the physical and functional interaction between proteins involved in transcription regulation 
such as the RNA Polll subunit Rpb4. the transcription factor p53. and adaptor proteins of the chromatin modifier complexes. 
The RNA polymerase II is composed of a ten-subunit core and a two-subunit dissociable subcomplex comprising the forth and the 
seventh largest subunits. Rpb4 and Rpb7. In Drosophila. Rpb4 is a product of a bicistronic gene together with the ATAC histone acetyl-
transferase complex constituent ADA2a (Pankotai et al. 2010). The alignment of Ada2a and Rpb4-related sequences indicated that the two 
proteins share the same transcription unit. Comparison of the related protein and nucleotide sequences revealed that Ada2a and Rpb4 coding 
region are present in similar organization in 12 Drosophila species, other then D. melanogaster. however a similar gene organization in 
other organisms cannot be identified. We investigated the mechanism by which the two mRNAs are generated. From RT-PCR analysis we 
concluded that the shift between Ada2a and Rpb4 mRNA formation takes place by splice acceptor site selection. Ada2a protein has another 
distinct homolog in Drosophila. Ada2b which is present in the SAGA complex. Although the two proteins contain the same conserved 
domains and their interacting partners are rather similar, they are part of two distinct HAT complexes. We questioned what confers the 
complex specificity of the Ada2 adaptors, more precisely which regions are responsible for their interaction with different transcriptional 
coactivators. Firstly, different Ada2a/Ada2b or Ada2b/Ada2a hybrids proteins were generated by joining PCR fragments corresponding to 
functional domains of one and the other ADA2. All the hybrid plasmids were generated using the Gateway system and were successfully 
tested on western blot for their expression in Drosophila S2 cells. Since the chimeric structure of the proteins did not disturb their expres-
sion in S2 cells, plasmids suitable for embryo injections were generated. Our goal is to see if their expression will restore one or the other 
ADA2 function. The coding region of hybrid proteins were inserted into a P-element containing vector allowing site specific insertion and 
injected into Drosophila embryos. Two out of six plasmids are ready for in vivo analysis in Adala and Ada2h mutant background. 
Previous studies have shown that HATs. beside their ability to relax chromatin, can regulate many other factors through acetylation. 
including transcription factors (Wang et al. 2001). In mammalian system it was shown that the Gcn5-containing acetyltransferase complex 
(STAGA) plays a role in p53-dependent gene activation. Ada2b and Gcn5L proteins are identified as direct interacting partners of the p53 
transcription factor (Gamper and Roeder 2008). According to previous studies Drosophila p53 is a functional homolog of mammalian p53 
(Ollmann et al. 2000). We investigated whether the adaptor proteins of the HAT complex have any effect on p53 transcriptional activity. A 
plasmid containing three copies of rpr consensus binding site upstream of the luciferase gene was constructed. The reporter plasntid was 
cotransfected into S2 cells with different constructs expressing Ada2a. Ada2b or Ada3 proteins and performed luciferase assays. There 
was no significant change in transcriptional activity of the p53 responsive element. Although it was previously described that hAda3 can 
increase p53 trancriptional activity (Wang et al. 2001). perhaps in Drosophila S2 cells the efficiency of this interaction requires additional 
factors which can promote a significant response. We also tested plasmid vectors containing Drosophila melanogaster p53 (Dmp53) and 
a point mutant form of it (Dmp53K303R) in reporter assays. Expression of either the wild type or the mutant variant increased the activity of 
the reporter gene 20 fold compared to control. No significant change was observed in the level of transcriptional activation ability of the 
wild type and the mutant variant of Dmp53. Future in vivo studies are planned to understand the mechanism by which p53 is activated. 
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